Knygos.lt klubas Knygos.lt nariams
33,10 €
-30%
Įprastai
47,29 €
Targeting Oncogenic Driver Mutations in Lung Cancer
Targeting Oncogenic Driver Mutations in Lung Cancer
Knygos.lt klubas Knygos.lt nariams
33,10 €
-30%
Įprastai
47,29 €
  • Išsiųsime per 12–18 d.d.
The recent advances in the field of molecular diagnostic techniques have led to the identification of targetable alterations prompting a paradigm shift in the management of non-small cell lung cancer (NSCLC) and an era of precision oncology. This Element highlights the most clinically relevant oncogenic drivers other than EGFR, their management and current advancements in treatment. It also examines the different challenges in resistance to targeted therapies and diagnostic dilemmas for each on…

Targeting Oncogenic Driver Mutations in Lung Cancer (el. knyga) (skaityta knyga) | knygos.lt

Atsiliepimai

Aprašymas

The recent advances in the field of molecular diagnostic techniques have led to the identification of targetable alterations prompting a paradigm shift in the management of non-small cell lung cancer (NSCLC) and an era of precision oncology. This Element highlights the most clinically relevant oncogenic drivers other than EGFR, their management and current advancements in treatment. It also examines the different challenges in resistance to targeted therapies and diagnostic dilemmas for each oncogenic driver and the future direction of NSCLC management.

Knygos.lt klubas
Knygos.lt nariams
33,10 €
-30%
Įprastai
47,29 €
Kaina registruotiems pirkėjams
Prisijunkite ir už šią prekę
gausite 0,47 Knygų Eurų!?
Išsiųsime per 12–18 d.d.
Įsigykite dovanų kuponą
Daugiau

The recent advances in the field of molecular diagnostic techniques have led to the identification of targetable alterations prompting a paradigm shift in the management of non-small cell lung cancer (NSCLC) and an era of precision oncology. This Element highlights the most clinically relevant oncogenic drivers other than EGFR, their management and current advancements in treatment. It also examines the different challenges in resistance to targeted therapies and diagnostic dilemmas for each oncogenic driver and the future direction of NSCLC management.

Atsiliepimai

  • Atsiliepimų nėra
0 pirkėjai įvertino šią prekę.
5
0%
4
0%
3
0%
2
0%
1
0%
(rodomas nebus)